NASDAQ (usa) |
![]() |
6715.56 | -12.11 | -0.18% |
FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
DAX (german) |
![]() |
13465.51 | 235.94 | 1.78% |
NIKKEI 225 (japan) |
![]() |
22420.08 | 408.47 | 1.86% |
Hang - Seng (hong kong) |
![]() |
28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) |
![]() |
3391.61 | 17.53 | 0.52% |
KOSPI (korea) |
![]() |
2556.47 | 33.04 | 1.31% |
All Ordinaries (australia) |
![]() |
6005.30 | 28.90 | 0.48% |
BOVESPA (brazil) |
![]() |
74092.76 | -215.73 | -0.29% |
Supriya Lifescience Limited (NSE: SUPRIYA)
SUPRIYA Technical Analysis
1.5
As on 30th Apr 2025 SUPRIYA SHARE Price closed @ 645.15 and we RECOMMEND Buy for LONG-TERM with Stoploss of 594.23 & Sell for SHORT-TERM with Stoploss of 684.03 we also expect STOCK to react on Following IMPORTANT LEVELS. |
SUPRIYASHARE Price
Open | 669.60 | Change | Price | % |
High | 672.45 | 1 Day | -25.80 | -3.85 |
Low | 642.70 | 1 Week | -73.70 | -10.25 |
Close | 645.15 | 1 Month | -89.00 | -12.12 |
Volume | 229734 | 1 Year | 248.50 | 62.65 |
52 Week High 619.25 | 52 Week Low 175.95 |
NSE INDIA Most Active Stocks
IDEA | 7.12 | -1.66% |
SUZLON | 56.40 | -2.25% |
YESBANK | 17.72 | -1.50% |
IDFCFIRSTB | 64.89 | -3.05% |
GTLINFRA | 1.44 | -2.70% |
SONATSOFTW | 421.55 | 12.11% |
IOC | 137.86 | 1.53% |
RPOWER | 39.99 | -2.49% |
JIOFIN | 260.42 | 1.08% |
TATASTEEL | 140.08 | -1.00% |
NSE INDIA Top Gainers Stocks
SONATSOFTW | 421.55 | 12.11% |
VMM | 118.48 | 10.00% |
GLOBALVECT | 220.90 | 10.00% |
JETFREIGHT | 14.77 | 9.98% |
CEATLTD | 3332.00 | 8.87% |
PFOCUS | 112.95 | 7.85% |
BARBEQUE | 333.10 | 7.59% |
GOCOLORS | 785.90 | 7.28% |
RRKABEL | 1044.70 | 6.36% |
SILLYMONKS | 18.72 | 6.00% |
NSE INDIA Top Losers Stocks
SUPRIYA Daily Charts |
SUPRIYA Intraday Charts |
Whats New @ Bazaartrend |
SUPRIYA Free Analysis |
|
SUPRIYA Important Levels Intraday
RESISTANCE | 702.48 |
RESISTANCE | 684.09 |
RESISTANCE | 672.73 |
RESISTANCE | 661.36 |
SUPPORT | 628.94 |
SUPPORT | 617.57 |
SUPPORT | 606.21 |
SUPPORT | 587.82 |
SUPRIYA Target May 2025
4th UP Target | 1006.31 |
3rd UP Target | 875.17 |
2nd UP Target | 794.11 |
1st UP Target | 713.05 |
1st DOWN Target | 481.75 |
2nd DOWN Target | 400.69 |
3rd DOWN Target | 319.63 |
4th DOWN Target | 188.49 |
SUPRIYA Weekly Target
4th UP Target | 910.01 |
3rd UP Target | 839.00 |
2nd UP Target | 795.11 |
1st UP Target | 751.22 |
1st DOWN Target | 625.98 |
2nd DOWN Target | 582.09 |
3rd DOWN Target | 538.20 |
4th DOWN Target | 467.19 |
SUPRIYA Target2025
4th UP Target | 1896.58 |
3rd UP Target | 1525.59 |
2nd UP Target | 1296.28 |
1st UP Target | 1066.96 |
1st DOWN Target | 412.64 |
2nd DOWN Target | 183.32 |
3rd DOWN Target | -45.99 |
4th DOWN Target | -416.98 |
Supriya Lifescience Limited ( NSE INDIA Symbol : SUPRIYA )
Sector : N/A And Other Stocks in Same Sector
Sector : N/A And Other Stocks in Same Sector
SUPRIYA Synopsis Technicals View
50 Day EMA |
N/A (Short Term) |
N/A | |
100 Day EMA | N/A (Mid Term) | N/A | |
200 Day EMA | N/A (Long Term) | N/A | |
MACD (12 26 9) | N/A | N/A | |
RSI (14) | N/A | N/A | |
MFI (14) | N/A | N/A | |
CCI (20) | N/A | N/A | |
WILLIAM %R (14) | N/A | N/A | |
ADX (14) | N/A | N/A | |
PSAR | N/A | N/A | |
10 Day Avg Volume | N/A |
SUPRIYA Other Details
Segment | EQ | |
Market Capital | 0.00 | |
Sector | ||
Industry | ||
Offical website | > echo $website ; ?> |
SUPRIYA Address
![]() |
SUPRIYA Latest News
SUPRIYA Business Profile
N/A
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service